A Guilford company that uses artificial intelligence to help pharmaceutical companies discover new drugs said Tuesday it has inked a collaboration deal with a Japanese drug company.
InveniAI, a technology spinout of New Haven biotech BioXcel Therapeutics, said it will help Osaka, Japan-based Shionogi & Co. Ltd. to identify, evaluate and optimize new targets for drug discovery.
Under the deal, InveniAI said it will use its AI platform, AlphaMeld, to research and validate drug targets that align with Shionogi’s drug development and commercialization expertise.
Shionogi, which focuses on infectious diseases and pain and central nervous system disorders, will be responsible for developing, manufacturing and commercializing drugs that work against the targets proposed by InveniAI.
InveniAI said it could reap up to $200 million for each drug developed, through a combination of upfront payments, milestone-based payments and royalties.
Ryuichi Kiyama, who leads Shionogi’s pharmaceutical research division, said in a statement the collaboration will use the power of AI to automate the early drug discovery phase “by trawling vast datasets to identify targets, find candidate molecules and predict favorable outcomes.”
“This will ultimately help us reduce discovery times and get our medicines to patients who are living without favorable treatment options,” Kiyama said.
Read more about how Connecticut bioscience companies are using AI to speed up life-saving drug discoveries HERE.
Contact Natalie Missakian at news@newhavenbiz.com
